{"id":"eberconazole","rwe":[{"pmid":"40733830","year":"2025","title":"Fabrication of sodium alginate-hydroxypropyl methylcellulose based bioadhesive eutectogel of Eberconazole for improved anti-fungal activity.","finding":"","journal":"Carbohydrate polymers","studyType":"Clinical Study"},{"pmid":"40102300","year":"2025","title":"Development and Optimization of Eberconazole Nanostructured Lipid Carrier Topical Formulations Based on the QbD Approach.","finding":"","journal":"AAPS PharmSciTech","studyType":"Clinical Study"},{"pmid":"39040124","year":"2024","title":"Evaluation of MMV Pandemic Response Box compounds to identify potent compounds against clinically relevant bacterial and fungal clinical isolates in vitro.","finding":"","journal":"New microbes and new infections","studyType":"Clinical Study"},{"pmid":"38133442","year":"2023","title":"Medicines for Malaria Venture Pandemic Box In Vitro Screening Identifies Compounds Highly Active against the Tachyzoite Stage of Toxoplasma gondii.","finding":"","journal":"Tropical medicine and infectious disease","studyType":"Clinical Study"},{"pmid":"36138545","year":"2023","title":"Development and Evaluation of Topical Ethosomal Gel for Fungal Infections.","finding":"","journal":"Drug research","studyType":"Clinical Study"}],"tags":[{"label":"eberconazole","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"D01AC17","category":"atc"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"ebernet","offLabel":[],"synonyms":["eberconazole","ebernet","eberconazole nitrate"],"timeline":[],"approvals":[],"brandName":"Ebernet","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"eberconazole","explanation":"Imagine the fungal cell membrane as a protective shield. Eberconazole disrupts this shield, making it difficult for the fungus to grow and multiply. This ultimately leads to the death of the fungal cells, helping to treat fungal infections.","oneSentence":"Eberconazole works by inhibiting the growth of fungi through interference with the fungal cell membrane.","technicalDetail":"Eberconazole exerts its antifungal effects by targeting the fungal cell membrane, specifically inhibiting the ergosterol biosynthesis pathway, which is essential for maintaining membrane integrity and function."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/978","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=EBERCONAZOLE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:55:03.885575","biosimilars":[],"competitors":[{"drugName":"clotrimazole","drugSlug":"clotrimazole","fdaApproval":"1975-02-03","patentExpiry":"May 26, 2042","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"miconazole","drugSlug":"miconazole","fdaApproval":"1974-01-08","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"econazole","drugSlug":"econazole","fdaApproval":"1982-12-23","patentExpiry":"Aug 8, 2031","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"thiabendazole","drugSlug":"thiabendazole","fdaApproval":"1967-04-07","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"tioconazole","drugSlug":"tioconazole","fdaApproval":"1983-02-18","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"ketoconazole","drugSlug":"ketoconazole","fdaApproval":"1981-06-12","genericCount":19,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"sulconazole","drugSlug":"sulconazole","fdaApproval":"1985-08-30","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"oxiconazole","drugSlug":"oxiconazole","fdaApproval":"1988-12-30","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"sertaconazole","drugSlug":"sertaconazole","fdaApproval":"2003-12-10","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"fluconazole","drugSlug":"fluconazole","fdaApproval":"1990-01-29","genericCount":31,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"luliconazole","drugSlug":"luliconazole","fdaApproval":"2013-11-14","patentExpiry":"Sep 6, 2033","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"efinaconazole","drugSlug":"efinaconazole","fdaApproval":"2014-06-06","patentExpiry":"Oct 24, 2030","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"eberconazole","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"clotrimazole","brandName":"clotrimazole","genericName":"clotrimazole","approvalYear":"1975","relationship":"same-class"},{"drugId":"miconazole","brandName":"miconazole","genericName":"miconazole","approvalYear":"1974","relationship":"same-class"},{"drugId":"econazole","brandName":"econazole","genericName":"econazole","approvalYear":"1982","relationship":"same-class"},{"drugId":"thiabendazole","brandName":"thiabendazole","genericName":"thiabendazole","approvalYear":"1967","relationship":"same-class"},{"drugId":"tioconazole","brandName":"tioconazole","genericName":"tioconazole","approvalYear":"1983","relationship":"same-class"},{"drugId":"ketoconazole","brandName":"ketoconazole","genericName":"ketoconazole","approvalYear":"1981","relationship":"same-class"},{"drugId":"sulconazole","brandName":"sulconazole","genericName":"sulconazole","approvalYear":"1985","relationship":"same-class"},{"drugId":"oxiconazole","brandName":"oxiconazole","genericName":"oxiconazole","approvalYear":"1988","relationship":"same-class"},{"drugId":"sertaconazole","brandName":"sertaconazole","genericName":"sertaconazole","approvalYear":"2003","relationship":"same-class"},{"drugId":"fluconazole","brandName":"fluconazole","genericName":"fluconazole","approvalYear":"1990","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"018073","UNII":"V7O1U41C9B","CHEBI":"CHEBI:82862","INN_ID":"6680","UMLSCUI":"C0767000","ChEMBL_ID":"CHEMBL558722","KEGG_DRUG":"D07882","DRUGBANK_ID":"DB13656","PUBCHEM_CID":"72051","SNOMEDCT_US":"1187438001","SECONDARY_CAS_RN":"130104-32-4","MESH_SUPPLEMENTAL_RECORD_UI":"C118963"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":33,"therapeuticAreas":["Infectious Disease"],"atcClassification":{"source":"DrugCentral","atcCode":"D01AC17","allCodes":["D01AC17"]},"biosimilarFilings":[],"recentPublications":[{"date":"2025 Oct 15","pmid":"40733830","title":"Fabrication of sodium alginate-hydroxypropyl methylcellulose based bioadhesive eutectogel of Eberconazole for improved anti-fungal activity.","journal":"Carbohydrate polymers"},{"date":"2025 Mar 18","pmid":"40102300","title":"Development and Optimization of Eberconazole Nanostructured Lipid Carrier Topical Formulations Based on the QbD Approach.","journal":"AAPS PharmSciTech"},{"date":"2024 Aug-Oct","pmid":"39040124","title":"Evaluation of MMV Pandemic Response Box compounds to identify potent compounds against clinically relevant bacterial and fungal clinical isolates in vitro.","journal":"New microbes and new infections"},{"date":"2023 Nov 29","pmid":"38133442","title":"Medicines for Malaria Venture Pandemic Box In Vitro Screening Identifies Compounds Highly Active against the Tachyzoite Stage of Toxoplasma gondii.","journal":"Tropical medicine and infectious disease"},{"date":"2023 Jan","pmid":"36138545","title":"Development and Evaluation of Topical Ethosomal Gel for Fungal Infections.","journal":"Drug research"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Eberconazole, also known as EBERCONAZOLE, is a small molecule drug in the eberconazole class. It is currently owned by an unknown entity, and its target is not specified. Eberconazole is not FDA-approved for any indications, and its commercial status, patent status, and availability of generic manufacturers are unknown. Further research is needed to determine its safety profile and potential uses. As a result, there is limited information available on this compound.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}